Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial.
antiretroviral drugs
body weight
dolutegravir
pharmacokinetics
plasma concentrations
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
08
03
2021
received:
06
01
2021
accepted:
18
03
2021
pubmed:
26
3
2021
medline:
15
12
2021
entrez:
25
3
2021
Statut:
ppublish
Résumé
This study aims to evaluate the association between dolutegravir (DTG) pharmacokinetic parameters and weight changes in treatment-experienced people with HIV (PWHIV) from the Simpl'HIV study newly switched to a dual DTG-based regimen. We used multivariable linear regressions to evaluate the association between DTG pharmacokinetic parameters at week 48 (derived using an established model) and weight change between week 0 and week 48. We adjusted our model for potential confounders including CD4 nadir, female sex, African origin, age, weight at week 0 and presence of a non-nucleoside reverse transcriptase inhibitor-based regimen before switch to DTG. The analysis included data from 39 PWHIV. An average significant weight gain of 2.4 kg was observed between baseline and week 48. DTG plasma exposure was not significantly associated with weight gain, even after adjusting for potential confounders (P = .9). We found no significant association between DTG pharmacokinetic parameters and weight gain amongst PWHIV newly switched to a DTG-based dual regimen.
Substances chimiques
Anti-HIV Agents
0
HIV Integrase Inhibitors
0
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Piperazines
0
Pyridones
0
dolutegravir
DKO1W9H7M1
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4455-4460Informations de copyright
© 2021 British Pharmacological Society.
Références
Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614-622. https://doi.org/10.1001/jamainternmed.2013.3728 [published Online First: Epub Date].
Althoff KN, Smit M, Reiss P, Justice AC. HIV and ageing: improving quantity and quality of life. Curr Opin HIV AIDS. 2016;11(5):527-536. https://doi.org/10.1097/COH.0000000000000305 [published Online First: Epub Date].
Willig AL, Overton ET. Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence. Curr HIV/AIDS Rep. 2016;13(5):289-296. https://doi.org/10.1007/s11904-016-0330-z [published Online First: Epub Date].
Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infec Dis: An Official Pub Infec Dis Soc Ame. 2020;71(6):1379-1389. https://doi.org/10.1093/cid/ciz999 [published Online First: Epub Date].
Barcelo C, Guidi M, Thorball CW, et al. Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. Open Forum Infect Dis. 2020;7(1):ofz464. https://doi.org/10.1093/ofid/ofz464 [published Online First: Epub Date].
Bhagwat P, Ofotokun I, McComsey GA, et al. Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race. Open Forum Infect Dis. 2018;5(11):ofy201. https://doi.org/10.1093/ofid/ofy201 [published Online First: Epub Date].
Bakal DR, Coelho LE, Luz PM, et al. Obesity following ART initiation is common and influenced by both traditional and HIV−/ART-specific risk factors. J Antimicrob Chemother. 2018;73(8):2177-2185. https://doi.org/10.1093/jac/dky145 [published Online First: Epub Date].
Lake JE, Wu K, Bares SH, et al. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. Clin Infec Dis: An Official Pub Infec Dis Soc Ame. 2020;71(9):e471-e477. https://doi.org/10.1093/cid/ciaa177 [published Online First: Epub Date].
Calmy A, Tovar Sanchez T, Kouanfack C, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV. 2020;7(10):e677-e687. https://doi.org/10.1016/S2352-3018(20)30238-1 [published Online First: Epub Date].
Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020;7(10):e666-e676. https://doi.org/10.1016/S2352-3018(20)30241-1 [published Online First: Epub Date].
Lake JE, Wu K, Erlandson KM, et al. Risk factors for excess weight gain following swich to integrase inhibitor-based ART. Abstract 669. Conference on retroviruses and opportunistic infections. Seattle, 2019.
Kerchberger AM, Angert C, Mehta CC, et al. Integrase strand transfer inhibitors are associated with weight gain in women. Abstract 672. Conference on retroviruses and opportunistic infections. Seattle, 2019.
Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet. 1999;36(4):289-304. https://doi.org/10.2165/00003088-199936040-00004 [published Online First: Epub Date].
Bourgi K, Rebeiro PF, Turner M, et al. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. Clin Infec Dis: An Official Pub Infec Dis Soc Ame. 2020;70(7):1267-1274. https://doi.org/10.1093/cid/ciz407 [published Online First: Epub Date].
Kerchberger AM, Sheth AN, Angert CD, et al. Weight Gain Associated with Integrase Stand Transfer Inhibitor Use in Women. Clin Infec Dis: An Official Pub Infec Dis Soc Ame. 2020;71(3):593-600. https://doi.org/10.1093/cid/ciz853 [published Online First: Epub Date].
Koethe JR, Bian A, Rebeiro PF, et al. Greater weight gain after switch to INSTI-based regimen from NNRTI vs PI regimen. Boston: Abstract 668. Conference on retroviruses and opportunistic infections; 2020.
Burdet C, Peytavin G, Le M, et al. Drug concentrations and body weight gain in PLWH switch to 3TC and dolutegravir. Boston: Conference on retroviruses and apportunistic infections; 2020.
Eckard AR, McComsey GA. Weight gain and integrase inhibitors. Curr Opin Infect Dis. 2020, 33;(1):10-19. https://doi.org/10.1097/QCO.0000000000000616 [published Online First: Epub Date].
Menard A, Meddeb L, Tissot-Dupont H, et al. Dolutegravir and weight gain: an unexpected bothering side effect? Aids. 2017;31(10):1499-1500. https://doi.org/10.1097/QAD.0000000000001495 [published Online First: Epub Date].
Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infec Dis: An Official Pub Infec Dis Soc Ame. 2020;71(6):1379-1389. https://doi.org/10.1093/cid/ciz999 [published Online First: Epub Date].
Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol. 2010;39(5):1179-1189. https://doi.org/10.1093/ije/dyp321 [published Online First: Epub Date].
Sculier D, Wandeler G, Yerly S, et al. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for 1 the maintenance of HIV-1 suppression: 48-week results of the factorial, 2 randomized, non-inferiority SIMPL-HIV trial. PLoS Med. 2020;17(11):e1003421
clinicaltrials.gov. Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV) (NCT03160105). Secondary Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV) (NCT03160105). https://clinicaltrials.gov/ct2/show/NCT03160105?term=NCT03160105&draw=2&rank=1
European AIDS Clinical Society. GUIDELINES Version 9.0. October 2017 Secondary European AIDS Clinical Society. GUIDELINES Version 9.0. October 2017 http://www.eacsociety.org/files/guidelines_9.0-english.pdf
Aouri M, Calmy A, Hirschel B, et al. A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. Journal of mass spectrometry. JMS. 2013;48(5):616-625. https://doi.org/10.1002/jms.3200 [published Online First: Epub Date].
KKGT (Kwaliteitsbewaking Klinische Geneesmiddelanalyse en Toxicologie, The Hague, The Netherlands). Secondary KKGT (Kwaliteitsbewaking Klinische Geneesmiddelanalyse en Toxicologie, The Hague, The Netherlands) http://kkgt.nl/?lang=en
Barcelo C, Aouri M, Courlet P, et al. Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. J Antimicrob Chemother. 2019;74(9):2690-2697. https://doi.org/10.1093/jac/dkz217 [published Online First: Epub Date].
Beal SL, Scheiner L. NONMEM Users Guide. Ellicott City: Icon Development Solutions; 1989-2009.
Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503-512. https://doi.org/10.1007/bf01060893 [pubelished Online First: Epub Date].
Zhang J, Hayes S, Sadler BM, et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol. 2015;80(3):502-514. https://doi.org/10.1111/bcp.12639 [published Online First: Epub Date].
Lahiri CD, Mehta CC, Angert C, et al. Association between integrase inhibitor hair concentrations and weight gain in women. Abstract 457. Boston: Conference on retroviruses and opportunistic infections; 2020.
Yagura H, Watanabe D, Kushida H, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 2017;17(1):622. https://doi.org/10.1186/s12879-017-2717-x [published Online First: Epub Date].
Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Aids, 2001;15(1):71-75. https://doi.org/10.1097/00002030-200101050-00011 [published Online First: Epub Date].
Mugglin C, Calmy A, Gunthard HF, et al. Changes in weight after switching to dolutegravir containing antiretroviral therapy in the Swiss HIV Cohort Study. Basel: European AIDS Conference; 2019.
Tate T, Willig AL, Willig JH, et al. HIV infection and obesity: where did all the wasting go? Antivir Ther. 2012;17(7):1281-1289. https://doi.org/10.3851/IMP2348 [published Online First: Epub Date].
Mave V, Erlandson KM, Gupte N, et al. Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults. J Infect Dis. 2016;214(1):65-72. https://doi.org/10.1093/infdis/jiw096 [published Online First: Epub Date].
Achhra AC, Mocroft A, Reiss P, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016;17(4):255-268. https://doi.org/10.1111/hiv.12294 [published Online First: Epub Date].
Kumar S, Samaras K. The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Front Endoc (Lausanne). 2018;9:705. https://doi.org/10.3389/fendo.2018.00705 [published Online First: Epub Date].
Alexander SPH, Kelly E, Mathie A, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. Br J Pharmacol. 2019;176(Suppl 1):S1-S20. https://doi.org/10.1111/bph.14747 [published Online First: Epub Date].